SLC2A9 and metabolic dysfunction-associated steatotic liver disease: Common to all MASLD patients is the repression of the glucose transporters SLC2A1 and SLC2A2 while the fructose transporters SLC2A8 and SLC2A9 were significantly up‐regulated (Figures 4B and S5A).